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ABSTRACT 
Objective: The present investigation explores the possibilities of using the in vitro and in vivo root and leaf extracts of Withania somnifera for anti-
diabetic and anti-hyperlipidaemic effects on streptozotocin-induced diabetic rats.  
Methods: In vitro shoot cultures of Withania somnifera were raised by the axillary proliferation in nodal explants from a garden grown plant using 
Murashige and Skoog medium then in vitro raised roots and shoots were used for the anti-hyperglycemic and anti-hyperlipidaemic experiment. 
After 72 h of STZ administration, the fasting blood glucose levels were measured and the rats showing FBG level>220 mg/dl were considered to be 
diabetic and were used for the hyperglycemic study. In vitro and in vivo methanolic root and leaf extracts were orally administered daily to diabetic 
rats for eight weeks. After the treatment period, blood glucose and serum enzymes like aspartate transaminase (AST), alanine transaminase (ALT), 
alkaline phosphatase (ALP), total cholesterol, triglycerides, HDL-c high density lipoprotein-bound cholesterol, LDL-c low density lipoprotein-bound 
cholesterol, LDH, serum protein level, total phenolics and anti-oxidative analysis (DPPH and FRAP) were determined. 
Results: The levels of blood glucose, AST, ALT, ALP, LDH, HDL-c significantly increased by the use of in vitro methanolic root extracts compared to 
normal control rats. However, remarkable loss of total protein, albumin, albumin: globulin (A: G) ratio was reported in streptozotocin-induced 
diabetic rats by using in vitro root extracts. Methanolic in vitro root extract at the dose levels of 300 mg/kg body weight produced a significant 
decrease in fasting blood glucose (FBG) level by 102.65 with respect to initial fasting blood glucose level after 30 d of the treatment. In vitro root 
extract demonstrated highest DPPH and FRAP free radical scavenging activity, i.e. 86.55±1.77 and 48.87±2.55 than other extracts. 
Conclusion: It may be concluded that methanolic in vitro root extract W. somnifera at the dose (300 mg/kg) has more potent anti-hyperglycaemic 
activity than the other in vitro and in vivo extracts of leaf and root on streptozotocin induced diabetic rats and was also found to be similar in effect 
to that of the standard drug ‘Glibenclamide’. 
Keywords: Withania somnifera, Anti-diabetic, Anti-hyperlipidaemic, Diabetes mellitus, Streptozotocin, Anti-oxidant, DPPH, FRAP 




Withania somnifera Dunal (Solanaceae), known as Ashwagandha in 
Sanskrit or Winter cherry in English, is one of the most valued plants 
of the traditional Indian system of medicine. The plant is used in 
more than 100 formulations of Ayurveda, Unani and Siddha and is 
therapeutically equivalent of ginseng [1]; hence is called popularly 
as 'Indian ginseng.' Plants have been the major source of drugs for 
the treatment of diabetes mellitus (DM) in Indian medicine and 
other ancient systems in the world, and for a long time DM has been 
treated orally with herbal medicines or their extracts because plant 
products are frequently considered to be less toxic and is 
comparatively free from side effects than synthetic ones [2, 3]. 
Furthermore, after the recommendations made by the WHO on DM, 
investigations on hypoglycemic agents from medicinal plants have 
become more important and the search for more effective and safer 
hypoglycemic agents have continued to be an important area of 
active research. World Ethno-botanical information on medicinal 
plants reported that almost 800 plants can be used to control DM. 
Many herbs and plants have been described as possessing 
hypoglycemic activity when taken orally [2, 3]. Some of these plants 
have also been pharmacologically tested and have shown to be of 
immense value in human diabetes treatment. The pharmacological 
effect of the roots of W. somnifera is attributed to the presence of 
withanolides, a group of steroidal lactones [4]. Its leaves are used in 
Ayurvedic and Unani systems for treatment of tumors and 
tubercular glands [5]. A number of withanolide steroidal lactones 
have been isolated from the leaves of W. somnifera [6] and its 
positive effect on anti-bacterial, anti-fungal and anti-tumor 
properties reported by Glotter et al. 1973 [7] There are a number of 
reports elucidating the chemical and pharmacological properties of 
W. somnifera [8-10].  
W. somnifera is a shrubby plant cultivated in India, parts of East Asia 
and Africa which offers tremendous potential as an energizing 
medicinal herb. Ayurvedic practitioners have used the roots of this 
plant for centuries with success as a tonic to increase vitality and 
longevity, as well as to treat health conditions as diverse as tumors 
and arthritis. Recent laboratory studies have begun to confirm what 
Ayurvedic practitioners have known for years that W. somnifera 
deserves attention as an herbal therapy to ease or even eliminate 
many of today’s common health problems. Hypoglycemic activity of 
'Trasina' (an ayurvedic formulation) containing extract of W. 
somnifera as one of the important constituents has been established 
beyond doubt and this activity may be due to its antioxidant 
properties [11]. It is being in use for a pretty long time for all age 
groups and for both sexes and even during pregnancy without any 
side effects. The traditional uses and anti-diabetic activity of W. 
somnifera have been reviewed [12]. Hypoglycemic effects [13] and 
the effects of W. somnifera on insulin sensitivity in NIDDM rats [14] 
have been reported. The chemistry and nutritional properties of 
phenolic compounds, including flavonoids, have been extensively 
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reviewed [15]. Flavonoids are commonly found in all plants and also 
possess hypoglycemic and antidiabetic activities [16]. Therefore, the 
present study is aimed at determining the anti-oxidant, anti-diabetic 
and anti-hyperlipidaemic effects of in vivo and in vitro W. somnifera 
root (WSREt) and leaf (WSLEt) extracts on streptozotocin-induced 
DM rats. 
MATERIALS AND METHODS 
Plant material 
Seeds of W. somnifera were procured from the Central Institute of 
Medicinal and Aromatic Plants (CIMAP), Lucknow, India and the 
plants were grown in the experimental garden in Rama Devi 
Women’s University, Bhubaneswar, Odisha, India. The plants were 
collected in the month of August 2013, and the plant parts like root 
and leaf were selected for the anti-diabetic activity. In vitro shoot 
cultures of W. somnifera were raised by auxiliary proliferation in 
nodal explants from a garden grown plant using Murashige and 
Skoog [17] medium and the in vitro raised roots and shoots were 
used for the anti-hyperglycemic and anti-hyperlipidaemic 
experiment. 
Preparation of plant extracts 
Freshly collected in vitro and in vivo plant parts (leaf and root) was 
washed under running tap water, dried under shade and powdered 
with the help of mechanical grinder. The course powder was first 
digested with petroleum ether (40-60 °C) followed by extraction 
with methanol in Soxhlet apparatus for 48 h. The leaf and root 
extracts were filtered separately and concentrated under vacuum. 
The yield of the extracts from root and leaf was about 76 and 72 g, 
respectively with respect to the dried powder plant material. The 
methanolic and aqueous extracts were then separately suspended in 
Tween-80 (5% v/v) and screened for anti-hyperglycemic and anti-
hyper-lipidaemic activity. 
Animals 
The experiments were carried out on thirty-six male healthy adult 
albino wistar strain rats (150–180 g bw) procured from an authorized 
firm in Bhubaneswar. They were housed in plastic cages with filter 
tops under controlled conditions of 12 h light/12 h dark cycle, 50% 
humidity and 28±2 °C. They all received a standard pellet diet and 
water. The standard pellet diet contained 21% crude protein, 5% fat, 
4% crude fiber, 8% ash, 1% calcium, 0.6% phosphorus, 2% vitamins 
and 55% nitrogen free extract (carbohydrates). The animals were 
maintained in the department of pharmaceutical sciences as per the 
principles and guidelines of the ethical committee for animal care of 
Utkal University (Odisha, India) in accordance with the Indian National 
Law on AnimalCare and Use (CPCSEA). 
Experimental design and treatment 
The rats were injected with streptozotocin dissolved in sterile 
normal saline at a dose of 60 mg/kg bw, intra-peritoneally. The rats 
were then kept for the next 24 h on 5% glucose solution bottles in 
their cages to prevent hypoglycaemia [18]. After a fortnight, rats 
with moderate diabetes having glycosauria (indicated by Benedict’s 
test for urine) and hyperglycaemia with blood glucose range of 250–
300 mg/dl were used for the experiment. Blood was collected from 
the eyes (venous pool) by a sino-ocular puncture for the estimation 
of the blood glucose. 
In the experiment, a total number of 36 rats (30 diabetic-induced 
rats and six normal rats) were used. Diabetes was induced in rats 
two weeks before starting the treatment. The rats were divided into 
six groups in the following manner after the induction of 
streptozotocin diabetes and each group comprised of six rats.  
Group 1: Normally controlled rats received only saline water during 
the experimental period. Group 2: Diabetic controlled-freshly 
prepared streptozotocin in saline was administered in a single dose 
of 60 mg/kg body weight through intraperitoneally to overnight 
fasted rats and the animals were allowed to develop diabetes for two 
weeks. Group 3: Diabetic rats were daily treated with methanolic 
WSREt with a dose of 200 mg/kg body weight for eight weeks. 
Group 4: Diabetic rats were daily treated with methanolic in vitro 
WSREt with a dose of 200 mg/kg body weight for eight weeks. 
Group 5:Diabetic rats were daily treated with methanolic WSLEt 
with a dose of 200 mg/kg body weight for eight weeks. Group 
6:Diabetic rats were daily treated with methanolic in vitro WSLEt 
with a dose of 200 mg/kg body weight for eight weeks. 
Collection of samples 
The rats were carefully monitored every day. The blood sugar level 
of all the rats was determined. After eight weeks of treatment, the 
rats were sacrificed by cervical dislocation. Blood was collected and 
processed for the biochemical estimations. 
Estimation of blood glucose  
In vitro and in vivo plant parts (leaf and root extracts or 
glibenclamide were administered orally between 12:00-02:00 P. 
M. on a daily basis for a period of 0-56 d. The blood samples were 
collected from each treated group by puncturing the tail veins, and 
FBG levels were measured at 57 d. Glucose is oxidized by the 
enzyme glucose oxidase (GOD) to give D-gluconic acid and hydrogen 
peroxide. Hydrogen peroxide in the presence of enzyme peroxidase 
(POD) oxidizes phenol which combines with 4-amino-antipyrine to 
produce a red colored quinoneimine dye. The intensity of the color 
developed is proportional to glucose concentration in the sample. 
The blood samples were collected on the 56 th
Estimation of total cholesterol by enzymatic method 
 day (9:00-11:00 A. M) 
by cardiac puncture of the rats and serum were separated by 
centrifugation for the biochemical estimations of serum Total 
Cholesterol, Triglycerides, HDL cholesterol, LDL cholesterol AST: 
Aspartate transaminase, Alanine transaminase, Alkaline 
phosphatase, Lactate dehydrogenase, Albumin: Globulin. 
Cholesterol esterase (CHE) hydrolyzes cholesterol ester. Free 
cholesterol is oxidized by the cholesterol oxidase (CHO) to 
cholest-4-en-3-one and hydrogen peroxide. Hydrogen peroxide 
formed reacts with 4-aminoantipyrine and phenol in the 
presence of peroxidase (POD) to produce pink colored 
quinonimine dye. The intensity of color produced is proportional 
to the cholesterol concentration. 
Estimation of triglyceride 
Triglyceride in the sample is hydrolyzed by microbial lipases to 
glycerol and free fatty acids (FFA). Glycerol is phosphorylated by 
adenosine-5-triphosphate (ATP) to glycerol-3-phosphate (G-3-P) in 
the reaction catalyzed by glycerol kinase (GK). G-3-P is oxidized to 
dihydroxyacetone phosphate (DAP) in a reaction catalyzed by the 
enzyme glycerol phosphate oxidase (GPO).  
In this reaction, hydrogen peroxide is produced in equimolar 
concentration to the level of triglycerides present in the sample. 
Hydrogen peroxide reacts with 4-aminoantipyrine and 3,5-Dichloro-
2-hydroxybenzene sulfonic acid (DHBS) in a reaction catalyzed by 
peroxidase. The result of this oxidative coupling is quinone imine 
red colored dye. The absorbance of this dye in solution is 
proportional to the concentration of triglycerides in the sample. 
Estimation of HDL cholesterol by PEG/CHOD-PAP 
The VLDL and LDL fractions of serum sample are precipitated using 
PTA and then HDL in the supernatant is separated by centrifugation 
and measured for its cholesterol content. The enzyme cholesterol 
ester hydrolase (CHE) hydrolyzes the ester cholesterol. Then 
cholesterol is oxidized by cholesterol oxidase (CHO) to cholest-4-en-
3-one and hydrogen peroxide. Hydrogen peroxide in the presence of 
enzyme peroxidase (POD) reacts with 4-aminoantipyrine and 
phenol to produce a red colored complex whose absorbance is 
proportional to HDL cholesterol concentration. 
Estimation of LDL cholesterol by direct enzymatic method 
Direct determination of serum LDLc (low-density lipoprotein 
cholesterol) levels without the need for any pretreatment or 
centrifugation steps. The assay takes place in two steps. In the 1st 
step elimination of lipoprotein non-LDL Cholesterol and 2nd step is 
the measurement of LDL. The intensity of the color formed is 
proportional to the LDL concentration in the sample. 
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Estimation of aspartate aminotransferase (SGOT) by modified 
IFCC method 
SGOT (AST) catalyzes the transfer of amino group between L-
aspartate and α-ketoglutarate to form oxaloacetate and glutamate. 
The oxaloacetate formed reacts with NADH in the presence of 
malate dehydrogenase to form NAD. The rate of oxidation of NADH 
to NAD is measured as a decrease in absorbance which is 
proportional to the SGOT (AST) activity in the sample. 
Estimation of alanine aminotransferase (SGPT) by modified 
IFCC method 
SGPT (ALT) catalyzes the transfer of amino group between L-alanine 
and α-ketoglutarate to form pyruvate and glutamate. The pyruvate 
formed reacts with NADH in the presence of lactate dehydrogenase 
to form NAD. The rate of oxidation of NADH to NAD is measured as a 
decrease in absorbance which is proportional the SGPT (ALT) 
activity in the sample. 
Estimation of lactate dehydrogenase by UV kinetic IFCC method 
Lactate dehydrogenase (LDH) catalyzes the conversion of pyruvate 
to lactate and NADH to NAD. LDH activity in serum is directly 
proportional to the rate of decrease in the absorbance of NADH at 
340 nm. Assay temperature for the estimation was 37 °C. 
Estimation of alkaline phosphatase (ALP) by PNPP method in 
serum 
The determination of the activity of alkaline phosphatase in serum 
based on the hydrolysis of p-nitrophenyl phosphate (PNPP) by the 
enzyme with the formation of free p-nitrophenol. This compound is 
yellow in alkaline solution. The formation of yellow color can be 
spectrophotometrically read at 405 nm, which is directly 
proportional to the enzymatic activity of alkaline phosphatase in 
serum/plasma. 
Estimation of total protein, albumin and globulin by biuret and 
BCG dye binding method 
Proteins bind with copper ions in an alkaline medium of the biuret 
reagent and produce a purple colored complex whose absorbance is 
proportional to the protein concentration. Albumin in a buffered 
medium binds with bromocresol green (BCG) and produces a green 
color, whose absorbance is proportional to the albumin 
concentration. 
DPPH radical scavenging assay 
The free radical scavenging activity of in vivo and in vitro leaf and 
root extracts were measured using the 2, 2-diphenyl-1-picryl-
hydrazyl (DPPH) methods (19,20) One millilitre of in vivo and in 
vitro leaf and root crude extracts at concentration (200 µg/ml) was 
mixed with 5 ml of 0.004% (v/v) DPPH and finally extracts were 
dissolved in methanol. The above procedures were repeated with 
BHT using ascorbic acid and α–tocopherol as positive controls. The 
above procedures were repeated with BHT using ascorbic acid and 
α–tocopherol as positive controls and the absorbance of the samples 
were measured at 517 nm. Experiments were carried out in 
triplicate. The DPPH radical scavenging assay was calculated 
according to the formula.  





negative control (absorbance of solution with no samples) 
1
Ferric reducing anti-oxidant power assay 
-positive control (absorbance of solution with samples)  
The ferric reducing properties of in vivo and in vitro leaf and root 
extracts were determined using assay described by Yen and Chen 
[21]. One milliliter of leaf and root methanolic extract was mixed 
with 2.5 ml of potassium phosphate buffer (0.2M, pH 6.6) and 
1g/100 ml potassium ferricyanide. The mixture was incubated at 
500 °C for 20 min followed by trichloroacetic acid (10%) addition to 
stop the reaction and finally equal volume of distilled water followed 
by 0.5 ml ferric chlorate (0.1g/100 ml) (FeCl3
Anti-oxidant activity (%) = (A
) was added and 
incubated at room temperature for 30 min, absorbance was 
measured at 700 nm. The whole experiment was carried out in 
triplicate. The above procedures were repeated with BHT using 
ascorbic acid and tocopherol as positive controls. The percentage of 
antioxidative activity in the FRAP assay of the leaf and root extracts 






-negative control (Absorbance of the control reaction) 
1
Statistical analysis 
 positive control (Absorbance in the sample) 
All the results were expressed as mean±SD. The results were 
analyzed for statistical significance by one-way analysis of variance 
(ANOVA) and Dunnet’s multiple range test (Different alphabets were 
considered to be significant, p ˂ 0.05). 
RESULTS AND DISCUSSION 
Anti-diabetic property of normal plant extracts owes to their ability 
of correcting dysfunction of pancreatic β-cells restoring insulin 
output, hindering the intestinal absorption of glucose or to the 
facilitation of metabolites in insulin-dependent processes. Though 
numerous anti-diabetic plant genotypes have been identified, the 
journey for new plant genotypes, especially their key bioactive 
phyto-compounds would certainly be rewarding. Streptozotocin-
induced diabetes in rodent’s results in the development of 
nephropathy similar to early stage clinical diabetic nephropathy [22, 
23]. The present experiment was conducted to study the anti-diabetic 
activity of W. somnifera in rats to provide scientific evidence for its 
traditional usage in control of diabetes. Although methanolic in vitro 
and in vivo leaf and root extracts of W. somnifera revealed more or less 
recovery of loss body weight, but remarkable loss, body weight 
retrieval was demonstrated by aqueous in vitro root extracts, possibly 
due to strong glycemic control offered by the treatment. Strategically, 
the oral glucose tolerance test (OGTT) was more sensitive than fasting 
blood glucose (FBG) measure in being able to evaluate the effect of in 
vitro and in vivo leaf and root extracts in securing glycemic control, 
thereby leading to a reversal of normal glucose homeostasis in 
experimental diabetes rats. 
A remarkable decrease in blood glucose was observed in diabetic 
controls and this study demonstrated that the in vitro root extracts 
protects the diabetic rats from the massive decrease in blood 
glucose, when given orally, daily for thirty days. Streptozotocin 
treated diabetic rats demonstrated a significant recovery in final 
blood glucose, which was close to that of normal control rats. The 
rise in blood glucose was far less in the poorly controlled diabetic 
rats as compared to well-controlled diabetic rats. This is in 
agreement with earlier studies on diabetic rats [24]. 
Free radical scavengers are chemicals that interact with and 
neutralize free radicals, thus preventing them from causing cellular 
damage in the biological system [25]. DPPH is a dark colored 
crystalline powder composed of stable free radical molecules [26]. 
The antioxidant compounds neutralize the free radical activity of 
DPPH by transferring either electrons or hydrogen atoms to DPPH 
[27], thereby changing the color from purple to the yellow colored 
stable diamagnetic molecule, diphenyl picrylhydrazine. The degree 
of discoloration indicates the scavenging power of the extract or 
antioxidant in terms of hydrogen donating ability [28]. The effect of 
methanolic in vitro root extracts of W. somnifera on both DPPH 
scavenging assay and FRPA assay in streptozotocin-induced diabetis 
rats is shown in (table 1). From the result of the DPPH 
spectrophotometric assay, The methanolic in vitro root extract 
demonstrated highest DPPH free radical scavenging value (86.55) 
and FRAP value (48.87) than the other extracts of leaf and root in 
both DPPH and FRAP. 
A total of four leaf and root extract were examined on normal 
healthy, glucose loaded and streptozotocin-induced diabetes rats. 
The perusal of the results of anti-diabetic screening of leaf and bark 
extracts in normal healthy rats is shown in (table 2). This result 
clearly indicates that the extracts have no effect on normoglycemic 
animals, but have a significant role in reducing the elevated blood 
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glucose level, which implies it acts through the extrapancreatic 
pathways rather than stimulating insulin secretion and results in 
antihyperglycemic effect without affecting normal blood glucose 
level, which may be beneficial in case of mis-dosing. 
 
Table 1: Total phenolic and anti-oxidant activity of methanolic in vivo and in vivo root and leaf extract of W. somnifera 
Concentration 
(mg/ml) 
Total phenolic(ug/mg) Anti-oxidant 
Root extract Leaf extract Root extract Leaf extract 
DPPH FRAP DPPH FRAP 
In vivo-WSLEt-200 5.4±1.02 4.9±1.65c 59.22±2.66d 22.87±2.87d 42.78±3.76d 34.87±2.87d d 
In vitro-WSLEt-200 5.9±1.02 5.6±0.43c 68.99±2.43c 30.98±1.87c 53.99±1.78c 42.87±2.76c 
In vivo-WSREt-200 
c 
6.8±1.01 6.5±1.33b 77.21±1.54b 38.98±1.43b 62.82±1.84b 49.87±2.65b 
Iv vitro-WSREt-200 
b 
8.1±1.03 7.7±0.87a 86.55±1.77a 48.87±2.55a 71.99±2.87a 61.87±1.78a a 
Data pooled from a total of 3 experiments showing mean values within rows (between columns) followed by different alphabets (a, b c and d) in 
superscript are significantly different (P ≤ 0.05; Duncan’s New Multiple Range Test). 
 
Table 2: Effects of W. somnifera (L.) extracts on blood glucose, serum lipid profile, serum enzymes AST, ALT, ALP and LDH,total protein, 









Blood Glucose(mg/dl) 94.66±1.49 401±1.25bc 138.34±1.44 a 102.65±3.55 143.93±1.05b 118.65±3.65b b 
Total Cholesterol(mg/dl) 88.29±4.74 201.87±1.04d 117.86±1.75b 98.83±2.12c 138.96±1.98c 109.32±2.21c 
Triglyceride(mg/dl) 
c 
73.58±3.92 107.08±1.32e 90.37±1.68de 81.76±2.43d 105.91±1.33de 85.88±1.87d 
HDL Cholesterol(mg/dl) 
def 
24.66±1.53 27.06±1.88i 25.72±1.54fg 24.65±1.76f 25.76±1.95h 25.61±1.65i 
LDL Cholesterol(mg/dl) 
i 
48.25±5.23 81.37±2.65g 50.34±3.97def 48.43±1.32e 55.41±4.43f 49.36±1.23g 
AST(IU/l) 
g 
95.40±2.41 156.89±5.57b 84.60±4.09c 83.11±3.65e 96.41±5.75d 86.55±2.32ef 
ALT(IU/l) 
de 
71.61±3.07 144.49±4.45ef 88.52±5.27cd 81.54±2.43d 97.51±5.17de 89.79±1.21e 
ALP(IU/l) 
d 
39.01±1.82 52.66±2.12h 39.39±1.58f 39.08±1.34f 39.35±1.22g 39.22±0.99h 
LDH(IU/l) 
h 
197.33±6.25 383.6±6.94a 276.50±11.96ab 223.21±3.54a 295.23±7.79a 236.32±4.32a 
Total Protein(mg/dl) 
a 
7.84±0.9 8.53±0.41j 7.82±0.38gh 7.22±0.89g 7.98±0.43i 7.78±0.76j 
Albumin(gm/dl) 
j 
5.08±0.73 5.49±0.16jk 4.87±0.22ghi 4.10±0.77g 4.96±0.45ij 4.78±0.79k 
Globulin(gm/dl) 
jk 
2.55±0.45j 2.48±0.12klm 2.76±0.23ghij 2.09±0.61g 2.98±0.32ijk 2.54±0.45kl 
A: G ratio 
kl 
2.99±0.46 1.21±0.11jkl 1.76±0.24ghijk 1.96±0.04g 1.66±0.35ijkl 1.88±0.17klm klm 
Values are expressed as mean±SD of six samples from each group. Both WSREt and WSLEt were treated at 200 mg/kg body weight. WSREt: W. 
somnifera root extract, WSLEt: W. somnifera leaf extract, TC: Total Cholesterol, TG: Triglycerides, HDL cholesterol: High Density lipoprotein-bound 
cholesterol, LDL cholesterol: Low-density lipoprotein-bound cholesterol, AST: Aspartate transaminase, ALT: Alanine transaminase, ALP: Alkaline 
phosphatase, LDH: Lactate dehydrogenase, A: G ratio = Albumin in gm%/Globulin in gm%. 
 
The total phenolic content of methanolic in vitro and in vivo root and 
leaf extracts of W. somnifera are 5.9±1.02, 8.1±1.03, 4.9±1.65, and 
6.5±1.33 respectively. In vitro root extracts were comparatively 
more effective in the Oral Glucose Tolerance Test (OGTT) than in 
vitro and in vivo leaf and roots. There was a significant reduction in 
blood glucose level observed at the dose levels of 200 mg/kg of the 
in vitro root extracts as compared to other glucose-loaded control, 
which showed impaired glucose tolerance.  
The methanolic in vitro root extracts at the dose of 200 mg/kg 
produced a significant decrease of blood glucose level than other 
extracts. From the results obtained, it is clear that chronic 
administration of W. somnifera leaf and root extract to 
streptozotocin-induced diabetes rats demonstrated blood glucose 
reduction in a constant dose but exposure time-dependent manner. 
In streptozotocin-induced diabetic rats, among all the extracts of W. 
somnifera the metabolic in vitro root at the dose level of 300 mg/kg 
revealed the significant highest reduction (102.65) followed by in 
vitro leaf extract (118.65) in fasting blood glucose level when 
compared to diabetic control group at the end of 30 d experimental 
period whereas the in vivo leaf and root extract at the same dose 
revealed 143.93 and 138.34 reductions on the same day respectively 
(table 2). It indicates that the plant extracts exhibited similar effects 
as that of the standard drug, Glibenclamide (99.45). To determine 
whether there was a statistically significant difference in 
hypoglycemia achieved by the different time intervals chronically 
administered, the data were compared by using one-way analysis of 
variance and the individual groups were compared with a control 
group using Dunnet’s multiple range test (DMRT). The anti-
hyperglycemic action of the root extracts may be attributed either 
(i) to the potentiating of pancreatic secretion of insulin from existing 
β cells of islets of Langerhans or (ii) to the extrapancreatic 
mechanism like increased peripheral utilization of glucose through 
different enzymatic pathways [29]. Since neither in vitro nor in vivo 
methanolic root extracts of W. somnifera exerted any innate 
hypoglycemic effect on normoglycemic animals, instead significantly 
reduced the elevated blood glucose level resulting from induced 
diabetes, it implies that it acts through the extra-pancreatic 
pathways rather than stimulating insulin secretion and causes an 
anti-hyperglycemic effect without affecting normal blood glucose 
level. Antidiabetic agents commonly causing toxicity in overdose 
include sulphonylureas (i.e. chlorpropamide, glibenclamide) and 
insulins. When these drugs are taken in overdose are shown to cause 
hypoglycemia [30]. Interestingly, in our investigation, the in vitro 
nor in vivo root and leaf extracts did not show any hypoglycemic 
activity, unlike the standard anti-diabetic drug glibenclamide. Thus, 
the potential medicinal shrub W. somnifera may possibly utiliseas a 
harmless and effective therapeutic drug for various diseases other 
than diabetes. Water is generally used in traditional settings to 
prepare the plant decoctions for health remedies. Many natural 
products including pigments, enzymes and bioactive components 
are soluble in water, which explains the high yield of the extract 
[31]. Hypoglycemic effect of W. somnifera was also reported by some 
researchers [32-34, 35]. The events like potentiation of pancreatic 
secretion of insulin from existing β cells of Islets of Langerhans or to 
the extrapancreatic mechanism such as increased peripheral 
utilization of glucose through different enzymatic pathways may be 
attributed by the action of anti-hyperglycemic effect. 
Effect of administering WSREt and WSLEt to diabetic rats on serum 
lipids like TC, TG, serum high-density lipoprotein-bound cholesterol 
(HDL-c), and low-density lipoprotein-bound cholesterol (LDL-c) are 
presented in table 1. The rise in blood sugar is accompanied by the 
increase in TC, TG, LDL-c, and fall of HDL-c in diabetic rats. The 
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levels of serum TC TG and LDL-c were significantly increased in 
diabetic rats when compared to those of normal control rats, while 
the level of serum HDL-c (70%) was significantly decreased in 
diabetic rats when compared to that of normal control rats (table 1). 
The abnormal high concentration of serum lipids is mainly due to 
increase in the mobilization of free fatty acids from the peripheral 
fat deposits because insulin inhibits the hormone sensitive lipase 
production. However, administering WSREt and WSLEt to diabetic 
rats tends to bring the values to near normal. Thus, WSREt and 
WSLEt treatments exhibited hypocholesterolemic, hypotri-
glyceridemic and hypo phospholipidomics effects while at the same 
time increasing the HDL-c. Therefore, the elevated level of serum 
lipids in DM causes the risk of coronary heart disease. It has been 
well established that DM alters the normal metabolism of tissues 
like liver, kidney and heart. The administration of WSREt and WSLEt 
to diabetic rats tends to bring the values to near normal. W. 
somnifera is known to have antioxidant properties [36] and this may 
reduce the susceptibility of lipids to oxidation and stabilize the 
membrane lipids thereby reducing oxidative stress. 
The LDH levels were significantly increased in diabetic rats when 
compared to normal control rats. LDH levels showed a significant 
decrease in WSREt and WSLEt treated diabetic rats. Organs rich in 
LDH are the liver, heart and skeletal muscles. In myocardial 
infarction, serum LDH level begins to rise by 8-12 h of the attack, 
reaches to a peak within 48-72 h and returns to normal after 1-2 w. 
Elevated serum LDH levels indicate cardiac damage and a profound 
risk of coronary heart disease. The levels of total protein in serum 
and albumin and albumin: globulin (A: G) ratio in serum was 
significantly decreased in diabetic rats when compared to those of 
normal control rats. On the other hand, no change was observed in 
the level of serum globulin in diabetic rats when compared to that of 
normal control rats. The total protein levels in serum and albumin 
and A: G ratio in serum were significantly increased in diabetic rats 
treated with WSREt when compared to those of diabetic rats. Hypo-
albuminemia was observed in DM, which consists with another 
report in that the altered A: G ratio was observed in diabetic rats 
[37]. Distinct metabolic, renal alterations lead to a negative nitrogen 
balance, enhanced proteolysis and lowered protein synthesis in 
experimental diabetes [38]. The reversal of the changes by WSREt 
and WSLEt therapy may be proved that the insulin deficiency had 
been sufficiently corrected. Serum albumin and A: G ratio, as well as 
total protein never deviated from the normal range throughout the 
treatment period in WSREt and WSLEt, treated diabetic rats. W. 
somnifera has been reported to produce anabolic effects, enhancing 
the synthesis of certain modulator proteins in rat liver and 
increasing the body weight in humans [39]. The levels of total serum 
proteins were found to be markedly decreased in STZ-induced 
diabetic rats this study. Decreased protein content of serum in 
diabetic patients reported by Mahboob et al., (2005) [40] were 
implicated with elevated lipid peroxidation process and decreased 
anti-oxidant defensive system. Insulin generally has an anabolic 
effect on protein metabolism in that it stimulates protein synthesis 
and retards protein degradation [41]. Therefore, a relative 
deficiency of insulin, due to STZ-induced degradation of pancreatic 
insulin secreting β-cells, protein synthesis are perhaps decreased in 
all tissues. This may be responsible for the decreased level of serum 
proteins in diabetic rats. 
An increase in the activities of SGOT, SGPT and ALP in plasma might 
be mainly due to the leakage of these enzymes from the liver cytosol 
into the blood stream which gives an indication of the hepatotoxic 
effect of STZ [42]. The effects of administering WSREt and WSLEt to 
diabetic rats on and serum enzymes AST, ALT, and ALP are given in 
table 2. Streptozotocin administration increased liver function 
biomarkers such as ALP and ALT significantly in comparison with 
normal control rats [43]. The activities of serum enzymes like AST, 
ALT and ALP were significantly increased in the diabetic rats when 
compared to those of normal control rats. But the activities of serum 
AST, ALT, and ALP were significantly decreased in diabetic rats 
treated with WSREt at the dose of 200 mg/kg body weight when 
compared to those of diabetic rats. In the present study, the 
activities of AST, ALT, and ALP in serum were altered in DM. In 
diabetic animals, the changes in the levels of AST, ALT, and ALP are 
directly related to changes in metabolism in which the enzymes are 
involved. The increased activities of transaminases, which are active 
in the absence of insulin due to the availability of amino acids in the 
blood of DM and are also responsible for the increased 
gluconeogenesis and ketogenesis. The restoration of AST and ALT of 
their respective normal level was observed in the WSREt and WSLEt 
treated groups. AST and ALT levels also act as an indicator of liver 
function, hence the restoration of normal levels of these enzymes 
indicates that the normal functioning of the liver. Increased activities 
of serum ACP and ALP have been observed in streptozotocin 
diabetic rats [44]. Streptozotocin-treated diabetes caused lipid 
peroxide-mediated tissue damage in the pancreas, liver, kidney, and 
heart. The increase in the levels of these enzymes in diabetes may be 
as a result of the leaking out from the tissues and then migrating into 
the bloodstream [45]. Diabetes and hyperlipidemia also cause cell 
damage by altering the cell membrane architecture, which results in 
enhanced activities of ALP in diabetic rats. In WSREt, WSLEt treated 
groups; the cell damage might be reverted and which may lead to 
the decreased activities of ALP. Therefore, the present study clearly 
indicates that WSREt and WSLEt possess hypoglycaemic and 
hypolipidaemic activities in streptozotocin-induced DM rats. 
The mode of action could be either due to increased glycogenesis or 
decreased glycogenolysis or gluconeogenesis [46], and/or due to the 
insulin secretagogue effect of W. somnifera, which causes an 
increased glucose uptake and its utilization by cells [47]. The results 
obtained in this study are in good agreement with those observed by 
previous investigators in alloxan-induced diabetic rats [48-50]. 
According to Rerup et al.(1970) [51] Streptozotocin, beta cytotoxin 
induces “diabetes inducing agent” in a wide variety of animal species 
through a massive destruction of β-cells of the islets of Langerhans 
and resulting in the reduced synthesis and release of insulin. 
sulphonylureas produce hypoglycaemia by increasing the secretion 
of insulin from the pancreas and by increasing the glycogen 
deposition in the liver was report [52, 53], W. somnifera root 
contains different vital components like alanine, lysine, 
carbohydrates, iron, calcium, niacin and volatile oils was reported 
[54]. The increased insulin secretion in diabetic could be due to 
presence of alanine, leucine, [55] carbohydrate, niacin, iron and 
calcium in aqueous extract [56-58] and the various constituents in 
the volatile oil (indole alkaloids such as mahanine and 
mahanimbine, sesquiterpene such as cadinene and monoterpene 
such as dipentene) [59] in methanol extract of W. somnifera. 
Streptozotocin-treated animal’s receiving the root extract of W. 
somnifera demonstrated rapid normalization of blood glucose levels 
in comparison to control and this could be due to the possibility that 
some ‘β-cell’ were still active and were acted upon by W. somnifera 
to extract their insulin-releasing effect and clearly indicate that the 
action of W. somnifera is probably mediated by an enhanced 
secretion of insulin. The increase in plasma insulin concentration 
could also be due to the longer lasting stimulant effect on β-cells of 
pancreatic islets or due to pancreatic β-cell regeneration of W. 
somnifera. In untreated diabetic (control) rats, there was a 
significant rise in serum triglycerides and cholesterol content. 
Perhaps this occurrence was because of insulin deficiency 
activating a lipase enzyme that hydrolyzed the stored triglycerides 
and mobilizing copius amounts of fatty acids and glycerol into the 
blood stream [60], which got eventually converted to 
phospholipids and cholesterol [61]. Thus, hypertriglyceridemia and 
hyper-cholesterolemia are the two most commonly observed lipid 
anomalies associated with diabetes, leading to coronary heart 
disease and atherosclerosis. Administration of in vitro root extracts, 
significantly lowered serum triglycerides and cholesterol in STZ-
diabetic rats groups, thus implying their ability to improve the blood 
lipid profile. 
The present study reveals that the medicinal in vitro root extract 
effect of this plant was also found to be much comparable to that of 
the standard drug streptozotocin treated rats. It may be concluded 
that the methanolic in vitro root extract W. somnifera at the dose 
(200 mg/kg) had more potent anti-hyperglycaemic activity than the 
other in vitro and in vivo leaf and root extracts and was also found to 
be analogous effect to the standard drug ‘Glibenclamide.' In 
conclusion, the extract of W. somnifera root confirms the role in the 
treatment of diabetes mellitus and can form a part of therapy in its 
management. Streptozotocin-induced diabetic rats with root 
Jena et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 10, 85-91 
 
90 
extracts of the medicinal plant species W. somnifera resulted in a 
pronounced reduction of blood sugar level and normalization of 
biochemical (serum and urine) indices as hepatic/renal functional 
markers. Particularly, our finding revealed that the in vitro root has 
noteworthy glycemic control in diabetic rats will usher a possibility 
of designing and developing a potent bioactive anti-diabetic drug 
suitable for diabetic patients. The effectiveness of in vitro root 
extracts was found to be comparable to that of the standard drug 
glibenclamide in treated rats. Additionally, compared to natural 
roots in vitro roots would be a more efficient and fast-proliferating 
renewable resource that will ensure the round-the-year availability. 
Since the global scenario is now changing towards the use of plant 
products as alternative medicine, development of the modern drug 
from fast-proliferating roots of W. somnifera should be emphasized 
as an alternative and complementary medicine for the control of 
various diseases. 
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